Weill Cornell Medicine Oncology & Hematology

 

Videos
10:33

Weill Cornell Medicine Oncology & Hematology

Understanding PSMA in Advanced Prostate Cancer and Its Impact on Treatment Decisions

FEATURING David Nanus
  • 55 views
  • December 10, 2024
14:21

Weill Cornell Medicine Oncology & Hematology

Secondary AML: Best Therapy Options

FEATURING Pinkal Desai
  • 119 views
  • November 21, 2024
07:37

Weill Cornell Medicine Oncology & Hematology

Importance of Dose Adjustments of Avatrombopag to Maintain Efficacy in ITP Patients

FEATURING Weill Cornell Medicine Oncology & Hematology
  • 54 views
  • August 30, 2024
  • 1
14:13

Weill Cornell Medicine Oncology & Hematology

Defining High-Risk HR+/HER2- eBC: Clinical Pearls for Oncologists

FEATURING Eleonora Nicolò
  • 173 views
  • August 22, 2024
  • 1
22:07

Weill Cornell Medicine Oncology & Hematology

Urothelial Carcinoma: New Developments

FEATURING Cora Sternberg
  • 347 views
  • May 23, 2024
  • 2
19:17

Weill Cornell Medicine Oncology & Hematology

Inflammatory Breast Cancer - Diagnosis and Management Updates

FEATURING Massimo Cristofanilli
  • 497 views
  • May 15, 2024
  • 4
11:23

Weill Cornell Medicine Oncology & Hematology

ASCO® GI 2024 Insights: "The NEST-1 Trial - Neoadjuvant BOT/BAL in Resectable MMR-Proficient and -Deficient CRC"

FEATURING Pashtoon Kasi
  • 233 views
  • March 8, 2024
  • 2
31:28

Weill Cornell Medicine Oncology & Hematology

Year in Review: ctDNA in Colorectal Cancer

FEATURING Pashtoon Kasi
  • 608 views
  • March 8, 2024
  • 6
08:59

Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "SWOG S1826 Trial - Nivo-AVD vs. Bv-AVD in Older Patients (Aged 60+ Years) With Advanced Stage HL"

FEATURING Sarah Rutherford
  • 208 views
  • December 18, 2023
  • 1
13:16

Weill Cornell Medicine Oncology & Hematology

Monitoring Response to Therapy in mCRPC: What Parameters to Look at

FEATURING David Nanus
  • 82 views
  • September 26, 2023
23:38

Weill Cornell Medicine Oncology & Hematology

Radiation Combined With IO for the Treatment of SCLC

FEATURING Ashish Saxena
  • 202 views
  • July 21, 2023
  • 1
08:25

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Phase I Dose-Escalation Results of PSMA-TRT With Alpha-Radiolabeled Antibody 225Ac-J591 and Beta-Radioligand 177Lu-PSMA I&T"

FEATURING Scott Tagawa
  • 165 views
  • June 8, 2023
08:22

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Efficacy and Safety Analysis of Sacituzumab Govitecan by Trop-2 Expression and UGT1A1 Status in the TROPHY-U-01 Study for LA or mUC"

FEATURING Scott Tagawa
  • 165 views
  • June 8, 2023
05:18

Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare Treatment With 177Lu-PSMA-617 + SoC & SoC Alone in Pts With mHSPC"

FEATURING Scott Tagawa
  • 1,781 views
  • June 8, 2023
  • 3
07:15

Weill Cornell Medicine Oncology & Hematology

Eltrombopag in ITP: Learnings From the RAISE and EXTEND Trials

FEATURING James Bussel
  • 948 views
  • April 4, 2023
  • 2
04:49

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Updated Outcomes in TROPHY-U-01 Cohort 1-A Phase 2 Study of SG in Pts With mUC That Progressed After PT-Based Chemo and a CPI

FEATURING Scott Tagawa
  • 167 views
  • February 23, 2023
05:48

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blinded Phase II Study of Keto HC and Anti-PSMA Antibody J591 Labeled With 177Lu or 111In in Pts With High-Risk nmCRPC

FEATURING Scott Tagawa
  • 41 views
  • February 23, 2023
12:05

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Novel Guidelines for PSMA PET Staging of Prostate Cancer: When to Follow and When to Not

FEATURING David Nanus
  • 329 views
  • February 22, 2023
  • 3
29:05

Indy Hematology Review

Aggressive Lymphoma - Nursing and Allied Providers Symposium

FEATURING John Leonard
  • 20 views
  • September 6, 2022
27:15

Indy Hematology Review

Aggressive B-Cell and T-Cell Lymphomas: Emerging Therapies

FEATURING John Leonard
  • 35 views
  • September 6, 2022
02:29

Weill Cornell Medicine Oncology & Hematology

CLONEVO: Cell Cycle Inhibition to Target the Evolution of Urothelial Cancer

FEATURING Bishoy Faltas
  • 108 views
  • July 14, 2022
12:11

Weill Cornell Medicine Oncology & Hematology

Pain Management in Sickle Cell Disease

FEATURING Shivi Jain, James Bussel
  • 154 views
  • June 28, 2022
11:30

ASCO 2022 Conference Coverage

ASCO 2022 Expert Discussion: Current Treatment Approaches in Hemophilia

FEATURING James Bussel, Catherine Mcguinn
  • 55 views
  • June 20, 2022
09:13

Weill Cornell Medicine Oncology & Hematology

Eltrombopag for the Treatment of Children With Persistent and Chronic ITP: PETIT and PETIT2 Clinical Trials

FEATURING James Bussel
  • 35 views
  • June 17, 2022
10:29

ASCO 2022 Conference Coverage

ASCO 2022 Using cfDNA to Identify Guideline-Relevant Biomarkers for Therapy Selection in 14,000 Pts With mCRC

FEATURING Pashtoon Kasi
  • 219 views
  • June 15, 2022
  • 1
06:24

Weill Cornell Medicine Oncology & Hematology

SYK Inhibitors for the Treatment of ITP

FEATURING James Bussel
  • 181 views
  • April 6, 2022
  • 1
09:29

i3 Health

Updates in Mantle Cell Lymphoma

FEATURING John Leonard
  • 27 views
  • March 24, 2022
13:17

ASCO Genitourinary Cancers Symposium

ASCO GU 2022 Highlights on the ADCs in Advanced Urothelial Cancer: Clinical Perspective

FEATURING Scott Tagawa
  • 162 views
  • February 24, 2022
  • 2
12:29

ASH 2021 Conference Coverage on VuMedi

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

FEATURING Pinkal Desai
  • 518 views
  • December 23, 2021
  • 2
09:55

ASH 2021 Conference Coverage on VuMedi

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Therapy in AML

FEATURING Pinkal Desai
  • 102 views
  • December 23, 2021
08:38

ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias and MDS and COVID-19 Infection

FEATURING Pinkal Desai
  • 277 views
  • December 23, 2021
  • 2
10:27

Richard T. Silver

Splenomegaly in Polycythemia Vera: Clinical Significance and Relation to Myelofibrosis and Survival

  • 329 views
  • December 16, 2021
  • 1
21:36

2021 International Congress on Myeloproliferative Neoplasms

MPN Stem Cell Fitness and the Link to Clinical Outcomes

FEATURING Joseph Scandura
  • 23 views
  • December 15, 2021
15:12

2021 International Congress on Myeloproliferative Neoplasms

A Novel Machine Learning-Derived Dynamic Scoring System Predicts Risk of Thrombosis in Polycythemia Vera

FEATURING Ghaith Abu-Zeinah
  • 18 views
  • December 15, 2021
12:42

2021 International Congress on Myeloproliferative Neoplasms

Pediatric MPNs: An Unfamiliar Topic

FEATURING Nicole Kucine
  • 17 views
  • December 14, 2021
08:40

Weill Cornell Medicine Oncology & Hematology

WCLC 2021 Data From IMpower010: Characterization of Stage IB-IIIA NSCLC by Type and Extent of Therapy Prior to Adjuvant Atezo

FEATURING Nasser Altorki
  • 126 views
  • September 27, 2021
10:41

ecancer

EHA 2021 Update on 1L Ibrutinib + Venetoclax for CLL/SLL: Primary Analysis of the CAPTIVATE Study

FEATURING John Allan
  • 22 views
  • September 6, 2021
12:23

Weill Cornell Medicine Oncology & Hematology

Evaluating mCRPC Using 177LU-PNT2002 PSMA Therapy After 2L Hormonal Treatment: SPLASH Study

FEATURING Scott Tagawa
  • 54 views
  • August 10, 2021
11:45

Weill Cornell Medicine Oncology & Hematology

ASCO 2021 Data on PSMA-Targeted Alpha Emitter 225Ac-J591 in Men With mCRPC

FEATURING Scott Tagawa
  • 102 views
  • June 16, 2021
08:16

Weill Cornell Medicine Oncology & Hematology

Newly FDA-Approved Sacituzumab Govitecan for Advanced Urothelial Carcinoma: How Does It Compare to Single-Agent Chemo? What Is the OS Data in Locally Advanced Unresectable Disease?

FEATURING Scott Tagawa
  • 112 views
  • April 22, 2021
  • 1
15:35

3rd Annual Hematologic Malignancies Symposium

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve OS in FLT3m Disease? Are DA+Cytarabine+/-GO Beneficial for EFS in Untreated Patients? Is CPX-351 Better Than SoC Chemo?

FEATURING Gail G. Roboz
  • 126 views
  • April 8, 2021
  • 1
09:40

Weill Cornell Medicine Oncology & Hematology

Key Symptoms and HRQoL in Chronic ITP: How Much Does ITP Affect QoL? I-WISh Study Data

FEATURING James Bussel
  • 76 views
  • February 5, 2021
12:29

2nd SOHO Italian Conference

Managing Hodgkin Lymphoma: PET Adapted Strategies, Applying ECHELON-1 Trial Data to the Frontline Setting

FEATURING John Leonard
  • 230 views
  • December 8, 2020
  • 2
19:44

2nd SOHO Italian Conference

How I Treat DLBCL in 2020: Who Shouldn't Get Standard Treatment? Is Intensity Less Important Over Age 80? Can We Do Better Than R-CHOP? Why Do Targeted Strategies Fail?

FEATURING
  • 477 views
  • December 7, 2020
  • 4
18:23

Weill Cornell Medicine Oncology & Hematology

2020 Update on TPO Agents: How Effective Are They in Chemotherapy-Induced Thrombocytopenia, Severe Aplastic Anemia After Transplant, Inherited & Radiation Thrombocytopenia?

FEATURING James Bussel
  • 595 views
  • September 29, 2020
  • 4
17:03

Weill Cornell Medicine Oncology & Hematology

ITP Receptor Agonists Efficacy Analysis: Romiplostim, Eltrombopag and Avatrombopag - How Do They Work and When Should We Use Them? What Is the Optimal Dosing? What About Discontinuation and Side Effects?

FEATURING James Bussel
  • 849 views
  • September 29, 2020
  • 6
20:28

University of Miami's 2nd Biennial Miami Leukemia Symposium

Tailoring Therapies to Target Leukemia Stem Cells: PU-FITC Binding Assay Could Be Utilized to Select Patients That Are More Likely to Respond to Treatment With PUH71

FEATURING Monica Guzman
  • 23 views
  • May 14, 2020
18:43

PeerView Oncology

Management of R/R MCL: Ibrutinib and Acalabrutinib Data, Venetoclax Monotherapy, Combination Therapies & BTK Inhibitor AE Management

FEATURING Jia Ruan
  • 464 views
  • March 25, 2020
  • 3
08:56

PeerView Oncology

Management of R/R MCL: Lenalidomide w/ Rituximab & CAR T Therapy

FEATURING Jia Ruan
  • 633 views
  • March 25, 2020
  • 4
21:24

Weill Cornell Medicine Oncology & Hematology

Treatment Options for Older and Elderly Patients With AML: How to Use Newly Approved Agents in Frontline and Relapsed Setting

FEATURING Pinkal Desai
  • 963 views
  • March 4, 2020
  • 8
19:58

12th International Congress on Myeloproliferative Neoplasms

How Should We Treat Children w/ MPN: No Guidelines on Cytoreduction or Agents Choice, Limited Data on Interferon, PEG-Int Well Tolerated w/ Stable/Improved Counts

FEATURING Nicole Kucine
  • 5 views
  • January 29, 2020
17:00

12th International Congress on Myeloproliferative Neoplasms

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival

FEATURING Richard T. Silver
  • 22 views
  • November 25, 2019
28:30

12th International Congress on Myeloproliferative Neoplasms

Is There a Role of Transplantation for CML in the Era of TKIs?

FEATURING Koen Van Besien
  • 21 views
  • November 12, 2019
22:37

ESO Lymphoma Course

Common "Epigenetic" Somatic Mutations in Lymphoma: CREBBP, EP300, HDAC3, TET2, KMT2D, EZH2

FEATURING Ari Melnick
  • 48 views
  • September 12, 2019
33:55

ESO Lymphoma Course

Pathogenesis of Mature B-Cell Lymphomas: Germinal Center‐derived Lymphomas, Somatic Mutations, MALT1 Inhibitor, Metabolic Adaptation & SIRT3 Metabolic Target

FEATURING Ari Melnick
  • 89 views
  • September 12, 2019
40:14

UNMC Leukemia Symposium: Focus on Opportunities to Improve Care

Novel Treatment Options for AML and Overview of Related Trials - Moving from Standard 7+3 to Combinations and Targeting FLT3, CD33, BCL2 and IDH Inhibitors

FEATURING Gail J. Roboz
  • 383 views
  • July 19, 2019
  • 1
16:17

Indy Hematology Review

Treatment and New Trials in DLBCL - Modifications to R-CHOP Based on Clinical and Pathological Features, Prognostic Significance of MYC, DA-EPOCH-R Therapy

FEATURING John Leonard
  • 223 views
  • June 24, 2019
  • 1
11:24

Indy Hematology Review

Brentuximab Vedotin for Previously Untreated Peripheral T-cell Lymphpoma (ECHELON-2 trial) - New Standard of Care & Mantle Cell Lymphoma - Treatment and Review of Current Trials

FEATURING John Leonard
  • 236 views
  • June 7, 2019
  • 1
05:14

Indy Hematology Review

Axi cell CAR T-cell Therapy for Refractory DLBCL - Overview of ZUMA-1 and Other Top Trials Presented at ASH

FEATURING John Leonard
  • 191 views
  • June 7, 2019
  • 1